Moderna, Inc. (MRNA) Earnings Call Transcripts
Moderna, Inc.'s Latest Earnings Call - October 24, 2026
In the third quarter of fiscal year 2026, Moderna, Inc. reported significant advancements in its cancer immunotherapy pipeline, particularly with its lead candidate, Intismeran, in combination with pembrolizumab for melanoma treatment. The company highlighted a hazard ratio of 0.58 for recurrence-free survival (RFS), indicating a 42% reduction in the risk of recurrence or death compared to pembrolizumab alone. Management maintained its guidance for ongoing trials and expressed confidence in the potential for Intismeran to become a new standard of care in melanoma and other cancers, while also indicating ongoing studies in various tumor types. Revenue and earnings specifics were not disclosed in the transcript, but the positive clinical data could drive stock performance in the near term.
Reported metrics
| Metric | Value |
|---|---|
| Hazard Ratio for Distant Metastasis-Free Survival | 0.62 (positive) |
Guidance from management
Management maintained its guidance for ongoing trials and expressed confidence in the potential for Intismeran to become a new standard of care in melanoma and other cancers. They indicated ongoing studies in various tumor types, suggesting a broad application for Intismeran.
What management said
Yes. Actually, just as an interesting side note, investigator I ever visited -- when I joined BMS was Jeff Weber on an [indiscernible] trial. And Dr. Ribas here was the lead of the [indiscernible] trial, and the science was always better for [indiscernible]. It's a big program. They did a great job. So maybe I could ask Professor Ascierto just to give some clinical context. And then maybe you could just give some of ...
If I can add something, just coming back to the discuss and the right study for a formal comparison is not the ADNA, it's the SWOG because in the G, we have the pembrolizumab, we have the perioperative, okay? Probably if I was discussed and to discuss this aspect, I would have been used the SWOG trial, more than NADENA.
What analysts pressed on
Analysts raised questions regarding the potential for overall survival benefits based on the current RFS data and the implications of using investigator versus central review for trial endpoints. There were also inquiries about the ability to predict patient responses based on biomarkers, which remains uncertain at this stage.
Main topics on the call
- Intismeran Phase III Trial Results — The Phase III trial of Intismeran combined with pembrolizumab demonstrated a hazard ratio of 0.58 for RFS, translating to a 42% reduction in risk of recurrence or death. Management noted, 'the combination significantly i...
- Durability of Clinical Benefit — Management emphasized the durability of the clinical benefit observed in the trial, with a hazard ratio of 0.42 after 6 months, indicating sustained efficacy. 'The treatment effect... tells you scientifically what treatm...
- Safety Profile — The safety profile of Intismeran was consistent with previous findings, with no significant increase in serious adverse events compared to pembrolizumab alone. Management stated, 'there does not appear that Intismeran is...
- Future Trials and Expansion Potential — Management indicated ongoing trials for Intismeran in various cancers beyond melanoma, suggesting a broad potential application. 'We have Intismeran clinical trials in all of these tumor types,' highlighting the unmet ne...
Read the full Moderna, Inc. transcript (October 24, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 148 calls on record spanning January 10, 2020 to October 24, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 148 Moderna, Inc. earnings call transcripts on record, spanning January 10, 2020 to October 24, 2026. Based on this history, Moderna, Inc. reports quarterly. The most recent call on file is dated October 24, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- MRNA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 148
- First call
- January 10, 2020
- Most recent
- October 24, 2026
- Reporting cadence
- quarterly